aztreonam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
monobactam antibiotics	279	78110-38-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cayston aztreonam azonam azthreonam aztreon monobactam nebactam primbactam aztreonam lysine azactam	A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms. Molecular weight: 435.43 Formula: C13H17N5O8S2 CLOGP: -0.36 LIPINSKI: 1 HAC: 13 HDO: 4 TPSA: 201.58 ALOGS: -3.34 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cayston
aztreonam
azonam
azthreonam
aztreon
monobactam
nebactam
primbactam
aztreonam lysine
azactam

A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.

Molecular weight: 435.43
Formula: C13H17N5O8S2
CLOGP: -0.36
LIPINSKI: 1
HAC: 13
HDO: 4
TPSA: 201.58
ALOGS: -3.34
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.23	g	Inhal.solution
4	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	10 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	68 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	305.44 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	1 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.18 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.50 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.40 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.50 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Sept. 21, 2009	EMA	GILEAD SCIENCES IRELAND UC
Dec. 31, 1986	FDA	BRISTOL MYERS SQUIBB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Infective pulmonary exacerbation of cystic fibrosis	1732.65	24.19	363	7973	8454	63472232
Cystic fibrosis	418.16	24.19	95	8241	3201	63477485
Death	254.26	24.19	277	8059	374104	63106582
Lung transplant	229.73	24.19	58	8278	3070	63477616
Pulmonary function test decreased	216.35	24.19	58	8278	3889	63476797
Haemoptysis	212.55	24.19	94	8242	28632	63452054
Hospitalisation	201.07	24.19	130	8206	84951	63395735
Bacterial disease carrier	194.02	24.19	43	8293	1288	63479398
Bronchial secretion retention	181.94	24.19	47	8289	2726	63477960
Superinfection	160.46	24.19	42	8294	2565	63478121
Eosinophilia	144.61	24.19	67	8269	22689	63457997
Pseudomonas infection	131.42	24.19	51	8285	11162	63469524
Cystic fibrosis respiratory infection suppression	129.89	24.19	24	8312	277	63480409
Bronchospasm	116.43	24.19	53	8283	17227	63463459
Respiratory failure	115.01	24.19	100	8236	101758	63378928
Sinus operation	113.87	24.19	32	8304	2554	63478132
Scoliosis	103.63	24.19	39	8297	7849	63472837
Sleep disorder due to a general medical condition	96.93	24.19	42	8294	12146	63468540
Treatment noncompliance	90.39	24.19	58	8278	37267	63443419
Cough	86.64	24.19	145	8191	292598	63188088
Atelectasis	82.56	24.19	45	8291	21438	63459248
Off label use	82.23	24.19	233	8103	674229	62806457
Nonspecific reaction	77.07	24.19	23	8313	2269	63478417
Aggression	70.84	24.19	42	8294	23456	63457230
Lung disorder	67.93	24.19	60	8276	62201	63418485
Rib fracture	67.10	24.19	40	8296	22557	63458129
Sputum increased	62.87	24.19	20	8316	2439	63478247
Drug reaction with eosinophilia and systemic symptoms	59.14	24.19	43	8293	33793	63446893
Illness	54.95	24.19	48	8288	49011	63431675
Distal intestinal obstruction syndrome	52.71	24.19	12	8324	406	63480280
Wheezing	51.34	24.19	63	8273	95532	63385154
Forced expiratory volume decreased	49.14	24.19	20	8316	4948	63475738
Pancreatic failure	46.84	24.19	13	8323	990	63479696
Bronchiectasis	46.43	24.19	28	8308	16114	63464572
Impaired quality of life	45.13	24.19	26	8310	13757	63466929
Infection	42.27	24.19	93	8243	229080	63251606
Transplant	40.30	24.19	11	8325	787	63479899
Sinus disorder	40.19	24.19	30	8306	24523	63456163
Agranulocytosis	39.56	24.19	30	8306	25104	63455582
Pneumonia	39.05	24.19	140	8196	456627	63024059
Pulmonary haemorrhage	39.03	24.19	19	8317	7162	63473524
Anxiety	37.56	24.19	86	8250	217455	63263231
Pathogen resistance	34.98	24.19	17	8319	6381	63474305
Dyspnoea	33.54	24.19	173	8163	661140	62819546
Heart rate increased	32.28	24.19	50	8286	94188	63386498
Productive cough	31.27	24.19	40	8296	63168	63417518
Drug resistance	30.96	24.19	25	8311	22908	63457778
Atrial fibrillation	30.73	24.19	55	8281	116581	63364105
Chest discomfort	30.45	24.19	53	8283	109916	63370770
Drug ineffective	29.63	24.19	58	8278	1044707	62435979
Asthma	26.05	24.19	54	8282	127507	63353179

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Infective pulmonary exacerbation of cystic fibrosis	907.10	23.74	208	4940	6593	34945190
Cystic fibrosis	355.34	23.74	75	5073	1583	34950200
Lung transplant	307.43	23.74	69	5079	1955	34949828
Death	140.38	23.74	226	4922	397823	34553960
Hospitalisation	125.57	23.74	87	5061	56815	34894968
Eosinophilia	95.21	23.74	55	5093	26167	34925616
Pulmonary function test decreased	89.69	23.74	32	5116	4943	34946840
Cystic fibrosis respiratory infection suppression	87.70	23.74	17	5131	228	34951555
Haemoptysis	80.60	23.74	55	5093	34951	34916832
Pseudomonas infection	79.35	23.74	38	5110	12344	34939439
Respiratory failure	65.20	23.74	80	5068	108492	34843291
Rash maculo-papular	54.56	23.74	40	5108	28411	34923372
Sputum increased	53.35	23.74	18	5130	2352	34949431
Cystic fibrosis related diabetes	49.04	23.74	10	5138	176	34951607
Infection	48.20	23.74	63	5085	90852	34860931
Productive cough	46.54	23.74	41	5107	37772	34914011
Hepatic cytolysis	46.27	23.74	28	5120	14468	34937315
Pathogen resistance	45.71	23.74	24	5124	9458	34942325
Leukocytosis	42.04	23.74	32	5116	24033	34927750
Off label use	41.17	23.74	145	5003	419379	34532404
Infective exacerbation of bronchiectasis	40.44	23.74	10	5138	431	34951352
Lung disorder	39.49	23.74	36	5112	34660	34917123
Drug reaction with eosinophilia and systemic symptoms	35.14	23.74	33	5115	32979	34918804
Rash morbilliform	34.46	23.74	14	5134	3073	34948710
Distal intestinal obstruction syndrome	32.28	23.74	8	5140	348	34951435
Toxic epidermal necrolysis	31.81	23.74	26	5122	21620	34930163
Forced expiratory volume decreased	30.60	23.74	13	5135	3190	34948593
Condition aggravated	28.60	23.74	77	5071	192119	34759664
Cough	27.38	23.74	65	5083	150075	34801708
Cystic fibrosis hepatic disease	23.97	23.74	4	5144	21	34951762

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Infective pulmonary exacerbation of cystic fibrosis	2039.29	21.05	450	10874	12401	79720663
Cystic fibrosis	565.17	21.05	127	11197	3753	79729311
Lung transplant	405.04	21.05	100	11224	4461	79728603
Eosinophilia	243.91	21.05	122	11202	45223	79687841
Pulmonary function test decreased	239.82	21.05	74	11250	7563	79725501
Haemoptysis	222.41	21.05	123	11201	55876	79677188
Death	216.17	21.05	328	10996	566186	79166878
Hospitalisation	205.14	21.05	141	11183	94095	79638969
Bacterial disease carrier	184.23	21.05	43	11281	1503	79731561
Bronchial secretion retention	164.42	21.05	48	11276	4056	79729008
Cystic fibrosis respiratory infection suppression	148.90	21.05	29	11295	415	79732649
Pseudomonas infection	138.75	21.05	65	11259	20838	79712226
Superinfection	130.97	21.05	42	11282	4860	79728204
Sinus operation	112.13	21.05	32	11292	2493	79730571
Bronchospasm	102.44	21.05	56	11268	24803	79708261
Sputum increased	100.98	21.05	34	11290	4579	79728485
Scoliosis	99.14	21.05	38	11286	7426	79725638
Respiratory failure	94.17	21.05	122	11202	180789	79552275
Drug reaction with eosinophilia and systemic symptoms	92.32	21.05	75	11249	64169	79668895
Sleep disorder due to a general medical condition	87.40	21.05	42	11282	14235	79718829
Off label use	81.17	21.05	297	11027	906918	78826146
Distal intestinal obstruction syndrome	78.71	21.05	19	11305	768	79732296
Treatment noncompliance	75.04	21.05	61	11263	52207	79680857
Nonspecific reaction	73.03	21.05	23	11301	2509	79730555
Forced expiratory volume decreased	70.06	21.05	30	11294	7784	79725280
Atelectasis	67.09	21.05	47	11277	32210	79700854
Pathogen resistance	66.63	21.05	35	11289	14307	79718757
Cough	66.59	21.05	155	11169	366634	79366430
Pancreatic failure	65.02	21.05	19	11305	1609	79731455
Infective exacerbation of bronchiectasis	63.81	21.05	16	11308	758	79732306
Lung disorder	63.01	21.05	67	11257	80490	79652574
Rash maculo-papular	55.51	21.05	53	11271	56025	79677039
Wheezing	51.97	21.05	73	11251	116591	79616473
Rib fracture	51.87	21.05	38	11286	27909	79705155
Bronchiectasis	49.80	21.05	34	11290	22352	79710712
Productive cough	49.72	21.05	62	11262	88269	79644795
Pneumonia	48.89	21.05	204	11120	660042	79073022
Toxic epidermal necrolysis	45.77	21.05	43	11281	44538	79688526
Impaired quality of life	42.21	21.05	26	11298	14360	79718704
Drug resistance	41.97	21.05	40	11284	42173	79690891
Cystic fibrosis related diabetes	41.76	21.05	9	11315	217	79732847
Transplant	41.30	21.05	12	11312	996	79732068
Aggression	40.92	21.05	43	11281	50915	79682149
Illness	40.51	21.05	41	11283	46470	79686594
Sinus disorder	40.46	21.05	30	11294	22434	79710630
Pneumonia pseudomonal	38.03	21.05	18	11306	5893	79727171
Hepatic cytolysis	37.51	21.05	31	11293	27120	79705944
Agranulocytosis	36.16	21.05	38	11286	44992	79688072
Toxicity to various agents	35.88	21.05	8	11316	421532	79311532
Dyspnoea	33.60	21.05	222	11102	856803	78876261
Leukocytosis	31.95	21.05	35	11289	43420	79689644
Rash morbilliform	31.41	21.05	16	11308	6134	79726930
Chest discomfort	29.07	21.05	62	11262	137982	79595082
Acute generalised exanthematous pustulosis	28.76	21.05	22	11302	17232	79715832
Disease complication	28.63	21.05	14	11310	4923	79728141
Pneumothorax	28.46	21.05	27	11297	28296	79704768
Fatigue	28.26	21.05	56	11268	929671	78803393
Toxic skin eruption	27.80	21.05	24	11300	22269	79710795
Asthma	26.54	21.05	59	11265	135036	79598028
Tracheostomy	26.36	21.05	9	11315	1263	79731801
Blood alkaline phosphatase increased	25.64	21.05	38	11286	63626	79669438
Sputum discoloured	24.30	21.05	22	11302	21721	79711343
Heart rate increased	24.02	21.05	53	11271	120671	79612393
Joint swelling	23.51	21.05	6	11318	288640	79444424
Anxiety	23.38	21.05	83	11241	248429	79484635
Diarrhoea	22.68	21.05	58	11266	880431	78852633
Pain in extremity	22.29	21.05	12	11312	364526	79368538
Cystic fibrosis hepatic disease	21.95	21.05	4	11320	39	79733025
Bronchopulmonary aspergillosis allergic	21.80	21.05	10	11314	3051	79730013
Peripheral swelling	21.21	21.05	6	11318	269611	79463453

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01DF01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Monobactams
FDA CS	M0014030	Monobactams
FDA EPC	N0000175493	Monobactam Antibacterial
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
CHEBI has role	CHEBI:36047	antibacterial drugs
CHEBI has role	CHEBI:50696	PBP3 inhibitor
CHEBI has role	CHEBI:88188	allergenic drug

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Septicemia due to Escherichia coli	indication	9323009
Infection due to Pseudomonas aeruginosa	indication	11218009
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Pneumonia due to Pseudomonas	indication	41381004
Peritonitis	indication	48661000
Lower respiratory tract infection	indication	50417007
Pneumonia due to Escherichia coli	indication	51530003
Klebsiella cystitis	indication	60867007
Urinary tract infectious disease	indication	68566005
Haemophilus influenzae pneumonia	indication	70036007
Infection due to Escherichia coli	indication	71057007
Bacterial infection due to Serratia	indication	71120004
Rhinoscleroma	indication	72409005	DOID:11336
Endometritis	indication	78623009	DOID:1002
Septicemia due to Serratia	indication	82091000
Female genital tract infection	indication	125585007
Infectious disease of abdomen	indication	128070006
Infection due to Enterobacteriaceae	indication	128945009
Bacterial infection due to Klebsiella pneumoniae	indication	186435004
Proteus pneumonia	indication	195888009
Bacterial peritonitis	indication	197171003
Proteus septicemia	indication	300986008
Escherichia coli urinary tract infection	indication	301011002
Proteus urinary tract infection	indication	301012009
Bacterial urinary infection	indication	312124009
Sepsis due to Pseudomonas	indication	448813005
Sepsis due to Gram negative bacteria	indication	449082003
Gram-Negative Aerobic Bacillary Pneumonia	indication
Serratia Urinary Tract Infection	indication
E. Coli Pelvic Inflammatory Disease	indication
Enterobacter Pneumonia	indication
Citrobacter Urinary Tract Infection	indication
Skin and Skin Structure Proteus Infection	indication
Skin and Skin Structure Pseudomonas Aeruginosa Infection	indication
Haemophilus Influenzae Bronchitis	indication
E. Coli Bronchitis	indication
Respiratory Cystic Fibrosis with Pseudomonas aeruginosa Colonization	indication
Skin and Skin Structure Serratia Infection	indication
Inflammatory Disease of Female Pelvic Organs	indication
Proteus Pelvic Inflammatory Disease	indication
E. Coli Endometritis	indication
Enterobacter Cloacae Bronchitis	indication
Serratia Bronchitis	indication
Pseudomonas Aeruginosa Bronchitis	indication
Citrobacter Peritonitis	indication
Aerobic Gram-Negative Bacteremia	indication
E. Coli Peritonitis	indication
Enterobacter Endometritis	indication
Skin and Skin Structure Citrobacter Infection	indication
Serratia Peritonitis	indication
Enterobacter Pelvic Inflammatory Disease	indication
Klebsiella Endometritis	indication
Pseudomonas Aeruginosa Urinary Tract Infection	indication
Klebsiella Pelvic Inflammatory Disease	indication
Bacterial Exacerbation of Acute Bronchitis	indication
Proteus Bronchitis	indication
Proteus Endometritis	indication
Klebsiella Pneumoniae Peritonitis	indication
Bronchospasm	contraindication	4386001
Kidney disease	contraindication	90708001	DOID:557
Disease of liver	contraindication	235856003	DOID:409
Pseudomembranous enterocolitis	contraindication	397683000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.44	acidic
pKa2	2.83	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Penicillin-binding protein 1A	Enzyme	PBPA_ECOLI	INHIBITOR	IC50	5.32	WOMBAT-PK	CHEMBL
Penicillin-binding protein 1B	Enzyme	PBPB_ECOLI	INHIBITOR	IC50	4.32	WOMBAT-PK	CHEMBL
Peptidoglycan synthase FtsI	Enzyme	FTSI_ECOLI	INHIBITOR	IC50	5.74	WOMBAT-PK	CHEMBL
Beta-lactamase	Enzyme	A4ZYU9_ECOLX		IC50	7.49	CHEMBL
AmpC	Unclassified	Q83TT7_ECOLX		IC50	7.22	CHEMBL
Efflux transporter; SugE	Transporter	Q3S5C3_SALNE		IC50	8.22	CHEMBL
Beta-lactamase	Enzyme	Q48435_KLEPN		IC50	8.22	CHEMBL
Beta-lactamase	Enzyme	B2ZTR6_ACIBA		Ki	8.15	CHEMBL
Beta-lactamase	Enzyme	D6NSM8_ACIBA		Ki	5.52	CHEMBL
Penicillin-binding protein 1A	Enzyme	PBPA_PSEAE		IC50	5.48	CHEMBL
Beta-lactamase	Enzyme	A2RP81_CITFR		Ki	5.70	CHEMBL

External reference:

ID	Source
D00240	KEGG_DRUG
827611-49-4	SECONDARY_CAS_RN
1272	RXNORM
C0004521	UMLSCUI
CHEBI:161680	CHEBI
T6O	PDB_CHEM_ID
CHEMBL158	ChEMBL_ID
CHEMBL3833340	ChEMBL_ID
D001398	MESH_DESCRIPTOR_UI
DB00355	DRUGBANK_ID
10763	IUPHAR_LIGAND_ID
5159	INN_ID
G2B4VE5GH8	UNII
5742832	PUBCHEM_CID
167898	MMSL
170132	MMSL
2813	MMSL
4239	MMSL
d00067	MMSL
373297006	SNOMEDCT_US
387386004	SNOMEDCT_US
409132008	SNOMEDCT_US
409133003	SNOMEDCT_US
69918003	SNOMEDCT_US
734461007	SNOMEDCT_US
90614001	SNOMEDCT_US
4017762	VANDF
4037186	VANDF
002807	NDDF
013342	NDDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
AZACTAM	HUMAN PRESCRIPTION DRUG LABEL	1	0003-2560	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	NDA	21 sections
AZACTAM	HUMAN PRESCRIPTION DRUG LABEL	1	0003-2560	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	NDA	21 sections
AZACTAM	HUMAN PRESCRIPTION DRUG LABEL	1	0003-2560	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	NDA	21 sections
AZACTAM	HUMAN PRESCRIPTION DRUG LABEL	1	0003-2570	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAMUSCULAR	NDA	21 sections
AZACTAM	HUMAN PRESCRIPTION DRUG LABEL	1	0003-2570	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAMUSCULAR	NDA	21 sections
AZACTAM	HUMAN PRESCRIPTION DRUG LABEL	1	0003-2570	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAMUSCULAR	NDA	21 sections
Aztreonam	HUMAN PRESCRIPTION DRUG LABEL	1	0409-0829	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	23 sections
Aztreonam	HUMAN PRESCRIPTION DRUG LABEL	1	0409-0830	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	23 sections
Aztreonam	HUMAN PRESCRIPTION DRUG LABEL	1	63323-401	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	24 sections
Aztreonam	HUMAN PRESCRIPTION DRUG LABEL	1	63323-401	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	24 sections
Aztreonam	HUMAN PRESCRIPTION DRUG LABEL	1	63323-401	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	24 sections
Aztreonam	HUMAN PRESCRIPTION DRUG LABEL	1	63323-401	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	24 sections
Aztreonam	HUMAN PRESCRIPTION DRUG LABEL	1	63323-401	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	24 sections
Aztreonam	HUMAN PRESCRIPTION DRUG LABEL	1	63323-401	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	24 sections
Aztreonam	HUMAN PRESCRIPTION DRUG LABEL	1	63323-402	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	2 g	INTRAMUSCULAR	ANDA	24 sections
Aztreonam	HUMAN PRESCRIPTION DRUG LABEL	1	63323-402	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	2 g	INTRAMUSCULAR	ANDA	24 sections
Aztreonam	HUMAN PRESCRIPTION DRUG LABEL	1	63323-402	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	2 g	INTRAMUSCULAR	ANDA	24 sections
Aztreonam	HUMAN PRESCRIPTION DRUG LABEL	1	63323-402	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	2 g	INTRAMUSCULAR	ANDA	24 sections
Aztreonam	HUMAN PRESCRIPTION DRUG LABEL	1	63323-402	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	2 g	INTRAMUSCULAR	ANDA	24 sections
Aztreonam	HUMAN PRESCRIPTION DRUG LABEL	1	63323-402	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	2 g	INTRAMUSCULAR	ANDA	24 sections